Spinocerebellar Ataxias Market to Grow Substantially During the Forecast Period (2023-2032) – DelveInsight | Key Companies – Seelos Therapeutics, VICO Therapeutics, Wave Life Sciences, Biohaven Pharma

Spinocerebellar Ataxias Market to Grow Substantially During the Forecast Period (2023-2032) - DelveInsight | Key Companies - Seelos Therapeutics, VICO Therapeutics, Wave Life Sciences, Biohaven Pharma
Delveinsight Business Research LLP
As per DelveInsight, the Spinocerebellar Ataxias Market is anticipated to evolve immensely in the coming years owing to the increase in the prevalent population of Spinocerebellar Ataxias patients in the 7MM, along with the expected entry of novel therapies in the market.

DelveInsight’s “Spinocerebellar Ataxias Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Spinocerebellar Ataxias market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Spinocerebellar Ataxias drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Spinocerebellar Ataxias treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Spinocerebellar Ataxias Market

Spinocerebellar Ataxias: An Overview

Spinocerebellar Ataxia (SCA) is a genetic disorder that is progressive, degenerative, and often fatal. The clinical marker of all SCAs is a progressive loss of balance and coordination accompanied by slurred speech. The mobility and communicative skills of individuals with an SCA are restricted, which strongly impairs quality of life, and many SCAs lead to premature death. Total 48 SCAs have been identified to date.

Genetically, the SCAs fall into two major groups: those caused by dynamic repeat expansion mutations (repeat expansion SCAs) and those caused by nonrepeating mutations. Further, repeat expansions are also a major cause of non-SCA inherited neurological diseases. There are at least 12 repeat expansion SCAs. Six of these diseases—SCA1, SCA2, SCA3/Machado–Joseph disease, SCA6, SCA7, and SCA17 are caused by translated CAG repeat expansion mutations that encode stretches of pure glutamine in the respective disease proteins; these diseases are thus referred to as polyglutamine SCAs. SCA3, also known as Machado-Joseph disease, is the most common type of SCA. SCA types 9 through 36 are rare and less well characterized.

Spinocerebellar Ataxias Market Key Facts

  • As per Bhandari et al. (2022), the global prevalence of spinocerebellar ataxia is 1 to 5 per 10,0000 and overall European prevalence is 0.9 to 3 per 10,0000 with some geographical variation i.e. 2/100000 in Italy. 

  • According to Sullivan et al. 2019, the global prevalence of SCA is 3 in 100,000, however, a wide regional variation exists. SCA3 is the commonest subtype around the globe.

  • According to DelveInsight’s analysis, the type-specific epidemiology of SCA, dentatorubral-pallidoluysian atrophy (DRPLA) was found to be more common in Japan when compared with other countries.

  • According to Lin et al. (2020), the pooled prevalence of hereditary ataxia is ~2.7–38.35 per 100,000; therefore, SCAs are considered as orphan diseases.

Spinocerebellar Ataxias Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Spinocerebellar Ataxias pipeline therapies. It also thoroughly assesses the Spinocerebellar Ataxias market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the market trend for each marketed Spinocerebellar Ataxias drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Spinocerebellar Ataxias Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Spinocerebellar Ataxias epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Spinocerebellar Ataxias epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Spinocerebellar Ataxias Epidemiology, Segmented as –

  • Total Prevalent cases of Spinocerebellar Ataxias [2019–2032]

  • Total Diagnosed Cases of Spinocerebellar Ataxias [2019–2032]

  • Type-Specific Cases of Spinocerebellar Ataxias [2019–2032]

  • Total Treated Cases of Spinocerebellar Ataxias [2019–2032]

Spinocerebellar Ataxias Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Spinocerebellar Ataxias market or expected to be launched during the study period. The analysis covers the Spinocerebellar Ataxias market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Spinocerebellar Ataxias drugs based on their sale and market share.

The report also covers the Spinocerebellar Ataxias pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Spinocerebellar Ataxias companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Spinocerebellar Ataxias Market Will Evolve and Grow by 2032 @ 


Spinocerebellar Ataxias Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Spinocerebellar Ataxias. Currently, Biohaven Pharmaceuticals is leading the therapeutics market with its Spinocerebellar Ataxias drug candidates in the most advanced stage of clinical development.

Spinocerebellar Ataxias Companies Actively Working in the Therapeutics Market Include

  • BioGene

  • Biohaven Pharmaceuticals


  • Seelos Therapeutics

  • Steminent Biotherapeutics

  • VICO Therapeutics

  • Wave Life Sciences

And Many Others

Emerging and Marketed Spinocerebellar Ataxias Therapies Covered in the Report Include:

  • Troriluzole: Biohaven Pharmaceuticals

  • Rovatirelin (KPS-0373): Kissei Pharmaceutical

  • IB1001: IntraBio

  • Stemchymal: Steminent Biotherapeutics


  • VO659: VICO Therapeutics

  • BIIB132: BioGene

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Spinocerebellar Ataxias Competitive Intelligence Analysis

4. Spinocerebellar Ataxias Market Overview at a Glance

5. Spinocerebellar Ataxias Disease Background and Overview

6. Spinocerebellar Ataxias Patient Journey

7. Spinocerebellar Ataxias Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Spinocerebellar Ataxias Treatment Algorithm, Current Treatment, and Medical Practices

9. Spinocerebellar Ataxias Unmet Needs

10. Key Endpoints of Spinocerebellar Ataxias Treatment

11. Spinocerebellar Ataxias Marketed Therapies

12. Spinocerebellar Ataxias Emerging Drugs and Latest Therapeutic Advances

13. Spinocerebellar Ataxias Seven Major Market Analysis

14. Attribute Analysis

15. Spinocerebellar Ataxias Market Outlook (In US, EU5, and Japan)

16. Spinocerebellar Ataxias Companies Active in the Market

17. Spinocerebellar Ataxias Access and Reimbursement Overview

18. KOL Views on the Spinocerebellar Ataxias Market

19. Spinocerebellar Ataxias Market Drivers

20. Spinocerebellar Ataxias Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Reports by DelveInsight

Hemostats Market

The global Hemostats market was valued at USD 3.64 billion in 2021, growing at a CAGR of 5.72% during the forecast period from 2023 to 2028 to reach USD 5.07 billion by 2028. The Hemostats market is expected to grow as a result of factors like the rise in surgical procedures, the increased emphasis on controlling blood loss during operations, and technological advancements in product development.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/